Abstract
Understanding the molecular mechanism of aging is of utmost importance to the scientific communities. To date, various theories have been proposed and many of them were evaluated as potential targets in the battle against aging. MicroRNAs, the universal gene expression regulators, were found to be associated with the aging process as many of them have been linked to biological process associated with cellular deterioration. In this short report, we briefly review the contribution of miRNAs to the aging process and offer an opinion as to how the knowledge of the role of these molecules in aging can be utilized.
Keywords: Aging, biomarkers, miRNA, therapeutic targets.
Graphical Abstract
Current Aging Science
Title:MicroRNAs and Aging: Biomarkers or Therapeutic Targets?
Volume: 10 Issue: 2
Author(s): Kyriacos Felekkis
Affiliation:
Keywords: Aging, biomarkers, miRNA, therapeutic targets.
Abstract: Understanding the molecular mechanism of aging is of utmost importance to the scientific communities. To date, various theories have been proposed and many of them were evaluated as potential targets in the battle against aging. MicroRNAs, the universal gene expression regulators, were found to be associated with the aging process as many of them have been linked to biological process associated with cellular deterioration. In this short report, we briefly review the contribution of miRNAs to the aging process and offer an opinion as to how the knowledge of the role of these molecules in aging can be utilized.
Export Options
About this article
Cite this article as:
Felekkis Kyriacos, MicroRNAs and Aging: Biomarkers or Therapeutic Targets?, Current Aging Science 2017; 10 (2) . https://dx.doi.org/10.2174/1874609808666161124130206
DOI https://dx.doi.org/10.2174/1874609808666161124130206 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents CDC25 Inhibitors as Anticancer Agents Are Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments
Current Medicinal Chemistry Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Significance of Genome-Wide Analysis of Copy Number Alterations and UPD in Myelodysplastic Syndromes using Combined CGH – SNP Arrays
Current Medicinal Chemistry Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Primary Lung Lymphoma
Current Drug Targets - Inflammation & Allergy Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Current Vascular Pharmacology Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Current Drug Targets Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology